Pourhassan Hoda, Agrawal Vaibhav, Pullarkat Vinod, Aldoss Ibrahim
Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA, United States.
Front Oncol. 2023 Aug 17;13:1237031. doi: 10.3389/fonc.2023.1237031. eCollection 2023.
Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia (ALL). Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining a frontline position in the ALL treatment paradigm. There have been multiple completed and ongoing studies showing significant promise with improved response rates and survival outcomes and decreased treatment toxicity and need for multi-agent chemotherapy regimens. The early use of blinatumomab has established success in Ph-negative and Ph-positive B-ALL, and this has extended to older adults with ALL who have historically had substantially inferior outcomes compared to their pediatric and young adult counterparts. Herein we will review the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions.
博纳吐单抗是一种双特异性T细胞衔接器，已在复发/难治性费城染色体（Ph）阳性和Ph阴性急性淋巴细胞白血病（ALL）中显示出疗效。鉴于其在晚期ALL中良好的安全性和活性，博纳吐单抗作为一种靶向免疫疗法正在迅速在ALL治疗模式中占据一线地位。已有多项完成的和正在进行的研究显示出显著的前景，包括提高缓解率和生存结果，以及降低治疗毒性和对多药化疗方案的需求。博纳吐单抗的早期使用已在Ph阴性和Ph阳性B-ALL中取得成功，这也扩展到了与儿科和年轻成人相比历史预后较差的老年ALL患者。在此，我们将回顾描述博纳吐单抗在新诊断的成人B细胞ALL中早期使用的当前数据以及未来方向。
